eFFECTOR Therapeutics (NASDAQ:EFTR) Trading Up 1.5%

Shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) shot up 1.5% on Wednesday . The stock traded as high as $2.13 and last traded at $2.08. 118,184 shares traded hands during mid-day trading, a decline of 62% from the average session volume of 307,054 shares. The stock had previously closed at $2.05.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of eFFECTOR Therapeutics in a report on Thursday, March 28th.

eFFECTOR Therapeutics Stock Up 1.5 %

The company’s fifty day moving average price is $7.88 and its two-hundred day moving average price is $10.74. The firm has a market cap of $7.68 million, a PE ratio of -0.12 and a beta of 0.94.

eFFECTOR Therapeutics (NASDAQ:EFTR) last announced its quarterly earnings data on Monday, March 25th. The company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.73) by ($0.69). As a group, analysts predict that eFFECTOR Therapeutics, Inc. will post -5.18 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in eFFECTOR Therapeutics stock. Sonora Investment Management Group LLC purchased a new position in shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 125,000 shares of the company’s stock, valued at approximately $75,000. Sonora Investment Management Group LLC owned 0.29% of eFFECTOR Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 57.67% of the company’s stock.

eFFECTOR Therapeutics Company Profile

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.